XL888 and pembrolizumab modulate the immune landscape of colorectal tumors in a phase Ib/II clinical trial.

We conducted a phase Ib/II clinical trial to evaluate the safety, feasibility, and clinical activity of combining pembrolizumab (anti-PD-1) with XL888 (Hsp90 inhibitor) in patients with advanced colorectal cancer (CRC). We hypothesized that this regimen would modulate soluble and cellular immune mediators and enhance clinical outcomes. The trial employed a 3 + 3 open-label design, with an expansion cohort at the recommended phase II dose (RP2D) in treatment-refractory, mismatch repair-proficient CRC patients.

Adherence with CPAP for patients with atrial fibrillation undergoing catheter ablation: A "real world" analysis.

Background: The relationship between Obstructive sleep apnea (OSA) and Atrial fibrillation (AF) is well established as existing literature has concluded that sleep apnea creates a unique, complex, and dynamic substrate for AF, with various pathophysiological mechanisms. Little is known regarding the role of CPAP therapy in reversing the risk of AF recurrence in patients with OSA. Awareness of the therapeutic effects of CPAP in preventing AF recurrence post-ablation will help create a multidisciplinary team of doctors to treat this complex population of patients.

Predictors of Atrial Fibrillation Freedom Post Ablation with the Pentaspline Pulsed Field Ablation Catheter: Sub-Analysis of the ADVENT Study.

Background: Pulsed field ablation (PFA) has proven to be at least non-inferior to thermal ablation for paroxysmal atrial fibrillation (PAF). Predictors of AF freedom for PFA have not yet been described.

Objective: Identify clinical and procedural predictors of treatment success in PAF patients treated with the pentaspline PFA catheter.

Anion exchange chromatography coupled to mass spectrometry for deciphering the complexity of a highly glycosylated fusion protein ("protein HGF").

Fc-fusion proteins are medicines developed for the treatment of complex diseases which feature enhanced pharmacokinetic properties compared to other therapeutic protein formats. A commonly used strategy for the extension of protein half-life in circulation is the introduction of negative charges on the protein, preferably through N- and O-glycans equipped with negatively charged sialic acid moieties. While enhancing pharmacokinetics, the presence of many glycosylation sites can coincide with a considerable protein heterogeneity, which renders analytical characterisation increasingly difficult.